Posted by Michael Wonder on 28 Jun 2022
Kyowa Kirin receives positive CHMP opinion for use of Crysvita (burosumab) for the treatment of tumour-induced osteomalacia
24 June 2022 - Crysvita could offer access to the first biologic treatment for EU patients with tumour-induced osteomalacia who cannot undergo surgical removal of tumours.
Kyowa Kirin today announced that the CHMP of the EMA has recommended that Crysvita (burosumab) be approved for the treatment of FGF23 related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
